[en] [en] INTRODUCTION: For several years, concerns about perfluoroalkyl and polyfluoroalkyl substances (PFAS) have been growing, and clinical laboratories may have to perform a growing number of PFAS analyses. The use of serum tubes without a separator gel is currently recommended for the quantification of PFAS due to the concern that the compounds may adsorb to the gel. The impact of gel adsorption on the accuracy of the results, however, has not been evaluated.
METHODS: Aliquots from a pool of blood spiked with PFAS were stored in gel-free clot activator tubes (CATs) and gel-containing BD SST II Advance tubes (serum separator tubes) for 2, 8, and 24 hours. The CATs and serum separator tubes were collected from 15 volunteers under typical sampling conditions. Concentrations of 16 PFAS were analyzed using liquid chromatography-tandem mass spectrometry, and the percentage of change in PFAS levels between both tube types was computed.
RESULTS: Results showed minimal changes (<5%) for most PFAS within 24 hours, except for long-chain perfluorosulfonates (including perfluorooctane sulfonate), which seemed to exhibit adsorption of the gel. In samples from volunteers, the observed changes were statistically significant for perfluorooctane sulfonate (P <.001).
DISCUSSION: Based on our analysis, we recommend using CATs to avoid PFAS underestimation.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Dufour, Patrice ; Centre Hospitalier Universitaire de Liège - CHU > > Service de toxicologie clinique, médicolégale, environnementale et en entreprise
Pirard, Catherine ; Université de Liège - ULiège > Département des sciences de la santé publique
Charlier, Corinne ; Université de Liège - ULiège > Département de pharmacie > Chimie toxicologique
Language :
English
Title :
Influence of separator gel in blood sampling tubes for perfluoroalkyl and polyfluoroalkyl substances analysis.
Glüge J, Scheringer M, Cousins IT, et al. An overview of the uses of per- and polyfluoroalkyl substances (PFAS). Environ Sci Process Impacts. 2020; 22: 2345-2373. https://doi.org/10.1039/d0em00291g
Abraham K, Mielke H, Fromme H, et al. Internal exposure to perfluoroalkyl substances (PFASs) and biological markers in 101 healthy 1-year-old children: associations between levels of perfluorooctanoic acid (PFOA) and vaccine response. Arch Toxicol. 2020; 94: 2131-2147. https://doi.org/10.1007/s00204-020-02715-4
Lam J, Koustas E, Sutton P, et al. The Navigation Guide - evidence-based medicine meets environmental health: integration of animal and human evidence for PFOA effects on fetal growth. Environ Health Perspect. 2014; 122: 1040-1051. https://doi.org/10.1289/ehp.1307923
Olsen GW, Ehresman DJ, Buehrer BD, Gibson BA, Butenhoff JL, Zobel LR. Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. J Occup Environ Med. 2012; 54: 974-983. https://doi.org/10.1097/JOM.0b013e31825461d2
Gleason JA, Post GB, Fagliano JA. Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. Environ Res. 2015; 136: 8-14. https://doi.org/10.1016/j.envres.2014.10.004
Zahm S, Bonde JP, Chiu WA, et al. Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid. Lancet Oncol. 2024; 25: 16-17. https://doi.org/10.1016/S1470-2045(23)00622-8
Lasters R, Groffen T, Eens M, Bervoets L. Dynamic spatiotemporal changes of per- and polyfluoroalkyl substances (PFAS) in soil and eggs of private gardens at different distances from a fluorochemical plant. Environ Pollut. 2024; 346: 123613. https://doi.org/10.1016/j.envpol.2024.123613
Li H, Hammarstrand S, Midberg B, et al. Cancer incidence in a Swedish cohort with high exposure to perfluoroalkyl substances in drinking water. Environ Res. 2022; 204: 112217. https://doi.org/10.1016/j.envres.2021.112217
Schümann M, Lilienthal H, Hölzer J. Human biomonitoring (HBM)-II values for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) - description, derivation and discussion. Regul Toxicol Pharmacol. 2021; 121: 104868. https://doi.org/10.1016/j.yrtph.2021.104868
Dasgupta A, Blackwell W, Bard D. Stability of therapeutic drug measurement in specimens collected in VACUTAINER plastic blood-collection tubes. Ther Drug Monit. 1996; 18: 306-309. https://doi.org/10.1097/00007691-199606000-00016
Garza KY, Carter J, Mercer A, et al. Evaluation of serum and rapid serum separator collection tubes for therapeutic drug assays. Clin Biochem. 2023; 115: 81-85. https://doi.org/10.1016/j.clinbiochem.2022.08.009
Schrapp A, Mory C, Duflot T, Pereira T, Imbert L, Lamoureux F. The right blood collection tube for therapeutic drug monitoring and toxicology screening procedures: Standard tubes, gel or mechanical separator ? Clin Chim Acta. 2019; 488: 196-201. https://doi.org/10.1016/j.cca.2018.10.043
Pirard C, Dufour P, Charlier C. Background contamination of perfluoralkyl substances in a Belgian general population. Toxicol Lett. 2020; 333: 13-21. https://doi.org/10.1016/j.toxlet.2020.07.015
Hölzer J, Lilienthal H, Schümann M. Human Biomonitoring (HBM)-I values for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) - Description, derivation and discussion. Regul Toxicol Pharmacol. 2021; 121: 104862. https://doi.org/10.1016/j.yrtph.2021.104862
